Related Experiment Video
Updated: Jun 18, 2026

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound
Published on: December 2, 2014
The interaction of endothelial nitric oxide synthase polymorphism and current smoking in terms of increased arterial
O Mayer1, J Filipovský, M Pesta
1University Hospital, Second Department of Internal Medicine, Charles University, Plzen, Czech Republic. mayero@fnplzen.cz
Abstract:
Nitric oxide belongs to the most important factors influencing structural and functional properties of vessel wall. Both genetic and environmental factors may influence its metabolism. The aim of this study was to explore whether two common polymorphisms of endothelial nitric synthase (eNOS) may, jointly with smoking, influence the stiffness of large arteries, quantified as pulse wave velocity (PWV). One hundred ninety four subjects free of manifest atherosclerotic disease or chronic pharmacotherapy were selected from population-based postMONICA study. PWV´s were measured using Sphygmocor® device between carotic and femoral arteries (aortic PWV) and between femoral and tibialis-posterior arteries (peripheral PWV). Two common polymorphisms, T786C and G894T, were assessed. Among current smokers, homo- or heterozygous carriers of T786C mutation showed significantly higher peripheral PWV than normal genotype carriers (14.0 vs 10.7 m/s, p<0.002); the same was true for the carriers of G894T mutation (13.9 vs 11.0 m/s, p<0.015). No differences were found in non-smokers, and neither of the eNOS polymorphisms influenced aortic PWV in our setting. In conclusion, genetically determined disorder of nitric oxide metabolism was associated with increased stiffness of peripheral, muscular-type arteries in generally healthy, untreated subjects, but only in the interaction with current smoking.
Related Concept Videos
Nitric Oxide Signaling Pathway
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Atherosclerosis I: Introduction
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

